Objective-Pulmonary artery smooth muscle cells (PASMCs) from neprilysin (NEP) null mice exhibit a synthetic phenotype and increased activation of Rho GTPases compared with their wild-type counterparts. Although Rho GTPases are known to promote a contractile SMC phenotype, we hypothesize that their sustained activity decreases SM-protein expression in these cells. Approach and Results-PASMCs isolated from wild-type and NEP −/− mice were used to assess levels of SM-proteins (SM-actin, SM-myosin, SM22, and calponin) by Western blotting, and were lower in NEP −/− PASMCs compared with wild-type. Rac and Rho (ras homology family member) levels and activity were higher in NEP −/− PASMCs, and ShRNA to Rac and Rho restored SM-protein, and attenuated the enhanced migration and proliferation of NEP −/− PASMCs. SMgene repressors, p-Elk-1, and Klf4 (Kruppel lung factor 4), were higher in NEP −/− PASMCs and decreased by shRNA to Rac and Rho. Costimulation of wild-type PASMCs with PDGF (platelet-derived growth factor) and the NEP substrate, ET-1 (endothelin-1), increased Rac and Rho activity, and decreased SM-protein levels mimicking the NEP knock-out phenotype. Activation of Rac and Rho and downstream effectors was observed in lung tissue from NEP −/− mice and humans with chronic obstructive pulmonary disease.
N eprilysin (NEP), a cell surface endopeptidase expressed in vascular cells, cleaves, and inactivates neuropeptides important for vasopressor responses.
1,2 NEP −/− mice show increased pulmonary vascular remodeling in response to hypoxia. 3 We have shown in NEP −/− pulmonary artery smooth muscle cells (PASMCs), persistent ET-1 (endothelin-1) signals synergize with PDGF (platelet-derived growth factor) to promote migration and proliferation. 4 Rho GTPases maintain vascular tone and a differentiated SMC phenotype by regulating Srf (serum response factor)-mediated transcription of SM-genes by contractile agonists. 5 In pathological states, such as pulmonary hypertension (PHTN) and chronic obstructive pulmonary disease (COPD), elevated levels of contractile agonists such as ET-1, promote vasoconstriction, and activation of Rho GTPases , . 6 Prolonged vasoconstriction promotes inward remodeling of resistance arteries. 7, 8 In animal models of PHTN, inhibition of Rho GTPases decreases neointima formation suggesting a role in vascular remodeling. 9, 10 Increased Rho (ras homology family member) activity inhibits myogenic differentiation of skeletal muscle and maintains bronchial SMCs in a mesenchymal phenotype. [11] [12] [13] [14] Whether sustained Rho GTPase activity enhances remodeling of pulmonary arteries by maintaining a mesenchymal/synthetic phenotype of SMCs is not known. In this study, we will begin to test this concept and examine mechanisms by which sustained Rho may suppress SM-protein levels in NEP
Increase in Baseline Activation of Rho GTPases in NEP −/− PASMCs
Rho GTPase (Rac and Rho) signaling plays a critical role in maintaining SM-protein levels through actin remodelinginduced Srf activity. 5 We measured Rac and Rho activity and Thr696 was 2-fold higher in NEP −/− PASMCs confirming increased Rho activity. In 4 of the 15 isolates of NEP −/− PASMCs tested, we observed a decrease in phospho and total cofilin levels compared with WT. Src mediated phosphorylation of cofilin at Tyr86 targets it for degradation and has been suggested as an alternate mechanism for controlling actin dynamics. 18 Decrease in cofilin activity by phosphorylation leads to stabilization of F-actin. 19 Phalloidin (F-actin) and DNase I (G-actin) stain were used to visualize F-and G-actin levels. NEP −/− PASMCs showed increased F-actin staining compared with WT ( Figure 2E ). F/G actin ratio measured by differential centrifugation showed 2-fold higher levels of F-actin in NEP −/− cells compared with WT ( Figure 2F ). Our results show that NEP −/− PASMCs exhibit sustained activation of Rac and Rho and downstream effectors.
ShRNA-Mediated Knockdown of Rac and Rho Restores SM-Protein Levels
To determine whether increased Rac and Rho activity suppresses SM-protein, we used shRNA to Rac and Rho, and examined effects on levels, in serum and PDGF-treated NEP −/− PASMCs. There was 70% to 80% knockdown of Rac and Rho proteins by shRNA treatment ( Figure IIIA and IIIB in the online-only Data Supplement). Cofilin phosphorylation was decreased by shRNA to Rho, and Mlc phosphorylation by Rac and Rho ( Figure IIIA through IIID in the online-only Data Supplement).
In WT PASMCs, shRNA to Rho decreased cofilin phosphorylation. Mlc can be phosphorylated by Rac and Rho. Mlc was weakly phosphorylated at baseline in WT cells and shRNA to either Rac or Rho caused compensatory increase in phosphorylation ( Figure IIIA and IIIB in the online-only Data Supplement).
ShRNA to Rac restored SM-proteins levels both at baseline and in PDGF-treated NEP −/− PASMCs. ( Figure 3A ; Figure IV in the online-only Data Supplement). ShRNA to Rho restored α-SMA and SM-MHCs levels but suppressed SM22 and calponin ( Figure 3A ; Figure IV in the online-only Data Supplement). These results suggest that Rho activity is required to maintain baseline expression of SM22 and calponin in NEP −/− PASMCs. In WT PASMCs, shRNA to Rac and Rho restored α-SMA levels decreased by PDGF treatment. ShRNA to Rho decreased SM-MHCs and calponin levels ( Figure VA and VB in the online-only Data Supplement) suggesting that Rho activity is required for their expression. However, SM22 levels were increased with Rho shRNA in WT cells suggesting that Rac activity could contribute to expression of SM22. We were unable to knockdown both Rac and Rho to confirm role on SM22 levels because the double knock-out cells did not grow.
Rho GTPases regulate cell migration and proliferation and contribute to mechanisms of vascular remodeling. 12 ShRNA to Rac and Rho attenuated baseline and serum and PASMCs assessed by immunofluorescence staining is shown in Figure 4F .
Elk-1 and Klf4 inhibit SM-gene expression by competing with myocardin for binding with Srf. 20, 21 We examined the levels of Srf associated with Elk-1, Klf4, and myocardin, by coimmunoprecipitation. There was a 2-fold increase in Srf associated with Elk-1 and Klf4 and a 0.5-fold decrease for myocardin in NEP −/− PASMCs compared with WT (data not shown).
ShRNA to Rac increased Srf expression, and shRNA to Rac and Rho significantly decreased levels of the repressors, p-Elk, and Klf4, in NEP −/− PASMCs treated with serum or PDGF ( Figure 4G ). Baseline levels were not significantly changed in these cells ( Figure 4G ). These results suggest that enhanced Rac and Rho activity increases levels 
NEP Substrate, ET-1, Synergizes With PDGF to Activate Rac and RhoA and Decreases SM-Protein Levels
Neuropeptide substrates of NEP and Src transactivate growth factor receptors and enhance PDGF-induced migration and proliferation of PASMCs. 4, 22 We tested whether simultaneous treatment with PDGF and ET-1 would suppress SM-protein levels in WT PASMCs, mimicking the NEP −/− phenotype. Cells were treated with PDGF in the absence or presence of ET-1, and activation of Rac and RhoA and downstream effectors, and levels of SM-proteins were measured. PDGF treatment increased Rho GTP levels by 2-fold and ET-1+PDGF caused a 2-fold increase in Rac and Rho GTP levels at 24 hours ( Figure 5A and 5B).
A time course (0 to 6 hours) for activation of downstream effectors of Rho GTPases in response to ET-1, PDGF, and ET-1+PDGF is shown in Figure 5C and fold change compared with control at 6 hours in Figure 5D . ET-1+PDGF increased total levels of Rac, Rho, and p-cofilin ( Figure 5C and 5D). ET-1 treatment increased phosphorylation of cofilin and PDGF increased phosphorylation of cofilin and Mlc at times tested ( Figure 5C and 5D ). ET-1 and PDGF cause sustained activation of Rac and Rho and downstream effectors. Levels of α-SMA, calponin, and SM22 were also decreased with ET-1+PDGF, as was observed in NEP −/− PASMCs ( Figure 5E and 5F) . Surprisingly, ET-1+PDGF 
Altered Phosphorylation of Rho Regulatory Proteins in NEP −/− PASMCs
To further understand the mechanism for sustained activation of Rac and Rho, we examined levels and phosphorylation status of their regulators. Rho GTPases are positively regulated by guanine nucleotide exchange factors (GEFs) and negatively by GAPs (GTPase activating proteins) and GDIs (guanine dissociation inhibitors). 11, 23 GAPs and GDI activities are regulated by phosphorylation by Src, Erk, and Rock 24 and activity of these kinases is increased in NEP −/− PASMCs. Tyrosine phosphorylation of RhoGDI by Src inhibits its activity resulting in activation of Rac and Rho. We assessed RhoGDI p-Tyr levels by immunoprecipitation of RhoGDI and probing with a pan-phospho-tyrosine (p-Tyr) antibody because of lack of a commercial site specific one ( Figure 6A ). Serine phosphorylation of p190RhoGAP by Rock or Erk inhibits its activity, leading to sustained activation of Rho. 24 We measured p190RhoGAP pSer/pThr by immune precipitation with p190RhoGAP antibody and probed with pan antibodies to p-Thr and p-Ser/Thr. p190RhoGAP was constitutively PASMCs were infected with either control shRNA or shRNA to Rac or Rho and selected with puromycin. Cells were treated with serum (0.2%) or PDGF (platelet-derived growth factor; 10 ng/mL) for 24 h and lysates were analyzed for SM-proteins. A shows effect of shRNA on SM-protein levels from 3 different isolates normalized to Gapdh. B shows the effect of shRNAs on migration and C shows on proliferation of NEP −/− PASMCs. *P≤0.05 for comparison between control and shRNA treatment. MHC indicates myosin; NEP, neprilysin; PASMC, pulmonary artery smooth muscle cells; and SMA, SM-actin.
phosphorylated at Ser/Thr residues in NEP −/− PASMCs suggesting inactivation. As seen in Figure 6B , p-Thr and p-Ser/Thr levels were also increased 2-fold in ET-1 and ET-1+PDGF-treated WT PASMCs.
Tyrosine phosphorylation of p190RhoGAP at Y1105 by Src increases its activity causing inhibition of Rho GTPases. Levels of p190RhoGAP Y1105 were significantly lower in NEP −/− PASMCs compared with WT. ShRNA to Rac increased p190-RhoGAP Y1105 levels 4-fold to 6-fold and shRNA to Rho 2-fold to 3-fold (Figure X in the online-only Data Supplement). We did not detect alterations in the levels of Vav or p115 GEF in these cells. Activity of RhoA/Rho-kinase pathway has been shown to higher in pulmonary arteries from patients with hypoxemic COPD. 6 We examined activation of Rho GTPases and downstream effectors in lungs from COPD patients with forced expiratory volume (FEV)>80% and FEV<50%. Lungs with forced expiratory volume 1 sec (FEV1)<50% showed increased Rac and Rho and downstream effectors p-cofilin and p-Mlc COPD patients with FEV1<50% also showed decrease in NEP ( Figure XI in the online-only Data Supplement) and increased levels of PDGF and ET-1 compared with lungs from COPD FEV1>80% (data not shown).
Rac and Rho and Their Downstream Effectors Are Increased in Lung Tissue
Taken together our results suggest that inactivation of Rho GTPase regulators by increase in phosphorylation of RhoGDI p-Tyr and p190RhoGAP p-Ser/Thr may contribute to sustained activation of Rho GTPases. We speculate that sustained ET-1 and PDGF levels in pathological conditions inactivate RhoGAP and RhoGDI by phosphorylation therefore increasing activities of Rac and Rho, and a dedifferentiated SMC phenotype as shown in the Graphic Abstract.
Discussion
Differentiated SMCs exist in a quiescent, contractile state and switch to a proliferative one in pathological conditions. Figure 5 . PDGF (platelet-derived growth factor) treatment in the presence of NEP substrate, ET-1 (endothelin-1), increases Rac and Rho activity and decreases SM-protein levels in NEP +/+ PASMCs. NEP +/+ PASMCs were treated with saline (C), PDGF (P; 10 ng/mL), ET-1 (E; 100 nmol/L), and PDGF+ET1 for different time points (0.75, 1.5, 3, and 6 h) and lysates probed for downstream effectors of Rho, transcription factors, and SM-proteins. A shows levels of Rac and Rho GTP bound form after 24 h treatment and graphical representation of average levels of GTPbound/total from 6 isolates is shown in B. C shows effect of agonists on levels of downstream effectors of Rho at different time points and D shows average fold change at 6 h compared with control from 3 different isolates normalized to Gapdh. E shows effect on SM-proteins at different time points and F shows average fold change at 6 h compared with control normalized to Gapdh. *P≤0.05 for comparisons between control and treated (n=3). MHC indicates myosin; NEP, neprilysin; PASMC, pulmonary artery smooth muscle cells; and SMA, SM-actin.
The regulation of SMC phenotype is complex and involves transcriptional repressors and signaling pathways, resulting in the downregulation of SM-proteins. 20, 21 GPCR-coupled contractile agonists including angiotensin II, norepinephrine, and ET-1, stimulate RhoA and its downstream effector Rock to maintain vascular tone, and promote a differentiated contractile SMC phenotype. However, studies have shown that prolonged contractile activity leads to musculurization of arteries because of increased SMC proliferation, and contributes to the pathogenesis of systemic and PHTN. [25] [26] [27] Our results show NEP −/− PASMCs, and WT PASMCs treated with ET-1, and PDGF have decreased expression of SM-proteins with increased Rac and Rho expression/ activity (Figures 1, 2, and 5 ). Rac and Rho activation is sustained by phosphorylation-dependent inactivation of RhoGDI and RhoGAP in NEP −/− PASMCs and in their WT counterparts treated with ET-1 and PDGF ( Figure 6 ; Graphic Abstract). These results suggest that sustained Rac and Rho activity can promote a synthetic SMC phenotype (Figures 1 and 2 ) and contribute to mechanisms important in vascular remodeling (Graphic Abstract). Rho and downstream effectors were also activated in lungs from NEP −/− mice. Genome-wide association studies have reported variants within the FAM13A (family with sequence similarity 13, Studies in transgenic mice have suggested a role for both Rac and Rho in vascular remodeling. Prolonged Rho activity is central to increased neointima formation in MLK3 −/− mice. 9 The prevention of medial thickening with Rho inhibitors observed in animal models of hypertension also support a role for Rho in vascular remodeling. 29 Mice with SM-specific deletion of Rac have enhanced Rho activation and are hypertensive. 30 Studies with mice overexpressing Vav, a common GEF for Rac and Rho, show that increased Rac activity contributes to vascular remodeling, whereas increased Rho contributes to hypertension. 31 Kailirin, a GEF for Rac in SMCs, promotes intima formation in atherosclerotic mice. 10 Our results demonstrate that that sustained Rac in NEP −/− PASMCs is more efficient than Rho in suppressing SM-protein expression (Figure 3) .
Rho mediated expression of SM-proteins is mediated by transcription factor, Srf, and repressed by Elk-1 and Klf4. 20 
NEP
−/− PASMCs express higher levels of SM-gene repressors, Elk-1, and Klf4. Transcriptional repression of SM-genes in response to injury and disease states plays an important role in vascular disease. 32 Klf4 is a transcription factor that is upregulated in human forms of PHTN and in proliferating SMCs. [33] [34] [35] [36] Modulation of Klf4 levels by Rho has not been reported in SMCs. However, sustained Rho activity is required for the repression of PKG (protein kinase G) by Klf4 in SMCs. 37 Whether increased Klf4 and sustained Rac /Rho activity is required for suppression of SM-proteins expression in NEP −/− PASMCs will need further investigation. Ambrisentan, an ETR A inhibitor, decreased p-Elk and Klf4 levels in NEP −/− PASMCs, suggesting that ET-1 contributes to the increased levels of these proteins ( Figure IX in the online-only Data Supplement). Muscularization of distal arteries contributes to the pathogenesis of PHTN and other vascular disorders. Understanding SMC phenotypes that contribute to this process maybe important in developing therapeutic strategies.
The Rho/Rho kinase pathway can be activated by several mechanisms involving receptor tyrosine kinases, GPCRs, or integrins. It has been suggested that the mechanism by which activity of Rho GTPases is increased, may depend on the stimulus and pathological context. 31 It is not known if the outcome and coupling to downstream effectors in the activation of Rac/ Rho activity may vary depending on whether the mechanism of activation involved GEFs, GAPs, or GDIs. Alternatively, matrix proteins like fibronectin activate Rac and Rho and suppress SM-protein expression. 13, 38 It is possible that alterations in the extracellular matrix of NEP −/− PASMCs couples Rac/ Rho to different effectors to promote dedifferentiation compared with that in WT cells. This possibility needs further investigation. Our data show that inactivation of RhoGDI and RhoGAPs by phosphorylation leads to sustained Rac/Rho activity and suppression of SM-contractile protein levels promoting a synthetic SMC phenotype.
